The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 02, 2024
Filed:
Apr. 15, 2019
National University Corporation Okayama University, Okayama, JP;
Niigata University, Niigata, JP;
National University Corporation Gunma University, Maebashi, JP;
Kawasaki Gakuenn Educational Foundation, Kurashiki, JP;
Masakiyo Sakaguchi, Okayama, JP;
Shinichi Toyooka, Okayama, JP;
Shuta Tomida, Okayama, JP;
Kazuhiko Shien, Okayama, JP;
Hiroki Sato, Okayama, JP;
Rie Kinoshita, Okayama, JP;
Junichiro Futami, Okayama, JP;
Kota Araki, Okayama, JP;
Mikio Okazaki, Okayama, JP;
Eisaku Kondo, Niigata, JP;
Yusuke Inoue, Maebashi, JP;
Akira Yamauchi, Kurashiki, JP;
National University Corporation Okayama University, Okayama, JP;
Niigata University, Niigata, JP;
National University Corporation Gunma University, Gunma, JP;
Abstract
Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.